Extramedullary hematopoiesis in cancer

Experimental & Molecular Medicine, Published online: 05 March 2024; doi:10.1038/s12276-024-01192-4Changes to hematopoiesis, or the creation of blood and immune cells, in cancers are the focus of this review by Barisas et al. They discuss conditions that promote extramedullary hematopoiesis (EMH), which produces blood cells outside the bone marrow. They also discuss the impact of tumor-derived factors, including interleukin-1α and leukemia inhibitory factor, on EMH. The team recently discovered that these specific factors stimulate the development of myeloid cells known for suppressing the immune system and aiding tumor growth. This suggests that targeting the pathways associated with these elements could be a new approach to cancer treatment. Research also indicates that EMH might be a common characteristic in other inflammation-related diseases, providing unique opportunities for further studies.This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author.
Source: Experimental and Molecular Medicine - Category: Molecular Biology Authors: Source Type: research